Miriam Bettencourt, MD
Dermatology · Las Vegas, NVNPI 1013934967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $613,936 of the $771,552 with a category attached, or 79.6%. 46 manufacturers reported payments, led by Amgen at 30.2% of the total. Reporting peaked in 2019 at $240,353 and has fallen 71.7% since, to $67,951 in 2025. Among dermatology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,026 payments — averaging $752.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$233K
- AbbVie$125K
- Bristol Myers Squibb$118K
- Pfizer$72K
- Dermavant Sciences, Inc.$64K
- Incyte Corporation$51K
- plus $108K from 40 others
What the payments were for
- Consulting fees$50,0956%
- Speaking & faculty fees$613,93680%
- Travel & lodging$74,44210%
- Food & beverage$32,9934%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$771,552 in reported general payments places this provider in the 95th percentile of 78 dermatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 27 | $2,039 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 72 | $1,024 |
| Clobetasol Propionate | 16 | $975 |
| Metronidazole | 20 | $842 |
| Ketoconazole | 53 | $839 |
| Doxycycline Hyclate | 32 | $736 |
| Fluorouracil | 11 | $728 |
| Clindamycin Phosphate | 11 | $355 |
| ValacyclovirValacyclovir Hcl | 12 | $334 |
| Mometasone Furoate | 17 | $275 |
| Triamcinolone Acetonide | 28 | $238 |
| Mupirocin | 17 | $140 |
| Hydrocortisone | 26 | $97 |
| Prednisone | 12 | $85 |
| Minoxidil | 13 | $67 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Las Vegas
- David CotterLas Vegas$1.4M
- Harry GreenbergLas Vegas$1.1M
- Victoria FarleyLas Vegas$151K
- Linda WoodsonLas Vegas$22K
- Candace SpannLas Vegas$18K
- Clifton HallLas Vegas$16K
- Jason StevensLas Vegas$15K
- Lionel HandlerLas Vegas$14K
- Frank RuecklLas Vegas$11K
- Susun MichaelsLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.